Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May 4:6:112.
doi: 10.3389/fonc.2016.00112. eCollection 2016.

Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC

Pranshu Bansal  1 , Diaa Osman  1 , Gregory N Gan  2 , George R Simon  3 , Yanis Boumber  4
Affiliations
Review

Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC

Pranshu Bansal et al. Front Oncol. .

Abstract

Lung adenocarcinoma is the most common subtype of non-small cell lung cancer (NSCLC). With the discovery of epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, and effective targeted therapies, therapeutic options are expanding for patients with lung adenocarcinoma. Here, we review novel therapies in non-squamous NSCLC, which are directed against oncogenic targets, including EGFR, ALK, ROS1, BRAF, MET, human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor receptor 2 (VEGFR2), RET, and NTRK. With the rapidly evolving molecular testing and development of new targeted agents, our ability to further personalize therapy in non-squamous NSCLC is rapidly expanding.

Keywords: ALK; BRAF; EGFR; HER2; NSCLC; ROS1; VEGFR2; c-MET.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Targeted pathways for NSCLC.
See this image and copyright information in PMC

References

    1. Ladanyi M, Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol (2008) 21(Suppl 2):S16–22.10.1038/modpathol.2008.12 - DOI - PubMed
    1. Skov BG, Høgdall E, Clementsen P, Krasnik M, Larsen KR, Sørensen JB, et al. The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population. APMIS (2015) 123(2):108–15.10.1111/apm.12328 - DOI - PubMed
    1. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer (2007) 7(3):169–81.10.1038/nrc2088 - DOI - PubMed
    1. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2012) 13(3):239–46.10.1016/S1470-2045(12)70227-9 - DOI - PubMed
    1. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 361(10):947–57.10.1056/NEJMoa0810699 - DOI - PubMed